Current treatment options |
Gemcitabine en cisplatine in de eerstelijn, geen geregistreerde geneesmiddelen voor de tweedelijn. |
Therapeutic value |
Possibly no place in the treatment regimen |
Substantiation |
Voldoet niet aan cieBOM NRS criteria; |
Duration of treatment |
Median 8.1 month / months |
Frequency of administration |
1 times a day |
Dosage per administration |
13.5 mg |
References |
SmPC, FIGHT-202 (NCT02924376); --https://www.fiercepharma.com/marketing/incyte-scores-fda-nod-for-rare-bile-duct-cancer-therapy-pemazyre.
-https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(20)30109-1.pdf |